Open Label Topical Beremagene Geperpavec (B-VEC)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dystrophic Epidermolysis Bullosa
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Trial Timeline
May 25, 2021 → Jul 31, 2023
NCT ID
NCT04917874About Open Label Topical Beremagene Geperpavec (B-VEC)
Open Label Topical Beremagene Geperpavec (B-VEC) is a phase 3 stage product being developed by Krystal Biotech for Dystrophic Epidermolysis Bullosa. The current trial status is completed. This product is registered under clinical trial identifier NCT04917874. Target conditions include Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa.
What happened to similar drugs?
0 of 2 similar drugs in Dystrophic Epidermolysis Bullosa were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04917874 | Phase 3 | Completed |
Competing Products
4 competing products in Dystrophic Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KB803 + Placebo | Krystal Biotech | Phase 3 | 44 |
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 29 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 37 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 22 |